CAR Beyond αβ T Cells: Unleashing NK Cells, Macrophages, and γδ T Lymphocytes Against Solid Tumors
Chimeric antigen receptor (CAR)-engineered cell therapy represents a landmark advancement in cancer immunotherapy. While αβ CAR-T therapy has demonstrated remarkable success in hematological malignancies, its efficacy in solid tumors remains constrained mainly by factors such as antigen heterogeneit...
Saved in:
| Main Authors: | Yunjia Xian, Lu Wen |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-06-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/13/6/654 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
CAR-NK cell therapy: promise and challenges in solid tumors
by: Sahar Balkhi, et al.
Published: (2025-04-01) -
CAR-armored-cell therapy in solid tumor treatment
by: Yan Liu, et al.
Published: (2024-11-01) -
mRNA‐Engineered CD5‐CAR‐γδTCD5‐ Cells for the Immunotherapy of T‐Cell Acute Lymphoblastic Leukemia
by: Zhixiong Zhu, et al.
Published: (2024-09-01) -
Clinical trials of nanoparticle-enhanced CAR-T and NK cell therapies in oncology: overcoming translational and clinical challenges - a mini review
by: Xiaoqian Zhao, et al.
Published: (2025-08-01) -
Advancing CAR-based cell therapies for solid tumours: challenges, therapeutic strategies, and perspectives
by: Sarkar Sardar Azeez, et al.
Published: (2025-07-01)